Ocugen to advance Phase 3 gene therapy assets following conference presentation

Ocugen to advance Phase 3 gene therapy assets following conference presentation
Ocugen unveils Phase 3 pipeline

Ocugen CEO Dr. Shankar Musunuri presented the company’s novel modifier gene therapy platform and three investigational assets currently in Phase 3 trials at the Stifel 2026 Healthcare Conference in New York City.

The update provides insight into Ocugen’s ongoing clinical development efforts in the biotechnology sector, emphasizing its strategy to advance late-stage gene therapy products.

Ocugen recently announced a modifier gene therapy that uses master regulator genes to target major blindness diseases through network effects, according to a company statement. The firm also signed a licensing agreement with Roots Pharmaceutical valued at up to $259 million in milestones and royalties for its OCU400 asset in the MENA region, as detailed in a previous deal disclosure. These moves support Ocugen’s current late-stage gene therapy focus.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.